We are excited to be attending Medica on 18-21 November 2019 in Dusseldorf, Germany.
We are excited to attend the CAI Annual Congress on 9-10 May 2019 in Croke Park. This is the highlight of the CAI Education Calendar, and includes high profile national and international speakers. Congress delegates can also attend workshops and breakout sessions throughout the meeting, with subspecialty sessions.
We are looking forward to attending the 24th Congress of the EAHP on 27-29 March 2019 in Barcelona.
The Congress theme is "Personalised Hospital Pharmacy – meeting the needs of every patient". The title itself says a lot. The origins of the pharmacy were very much personalised and recently we have been rediscovering the need for tailored medication and approach to treatment for different patient groups and individuals.
We are excited to be attending the European Oncology Convention – 26-27 March 2019 | Birmingham
Specialising in head and neck, GI, lung, GU & breast cancer, the European Oncology Convention will bring the world’s leading professionals in the oncology industry together for an unmissable two-days at NEC, Birmingham. Complete with an unrivalled line-up of 100 CPD accredited seminars, interactive workshops and state-of-the-art showcases from exclusively selected exhibitors, this event promises to show the revolutionary ways of studying and treating cancer.
We are excited to attend the CPhI Worldwide conference in Madrid on 9th to 11th October. This is one the world's leading pharmaceutical events. CPhI Worldwide, together with co-located events ICSE, InnoPack, P-MEC and FDF, hosts more than 45,000 visiting pharma professionals over three days. 2,500+ exhibitors from 153 countries gather at the event to network and take advantage of more than 150 free industry seminars.
The IMSTA’s Annual Conference 2018 which will focus on outcomes measurement. The excellent line of speakers will discuss how Ireland measures up, what will it take to make Slaintecare a reality, an example of using HTA as a driver, and the HSE’s plans for assessing the potential of medtech to improve outcomes.